A phase I study of RMC-035 to evaluate safety in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2018
At a glance
- Drugs RMC 035 (Primary)
- Indications Acute kidney injury; Preeclampsia
- Focus Adverse reactions
- 31 Jan 2018 According to an A1M Pharma AB media release, the company has submitted an application to the Swedish Medical Products Agency to conduct a clinical phase I study in healthy volunteers.
- 05 Jan 2018 According to an A1M Pharma AB media release, this trial is expected to last until the first quarter of 2019.
- 14 Nov 2017 According to an A1M Pharma AB media release, company is completing the application to initiate this study.